國立虎尾科技大學 |

Biomarkers in cancer therapy = liquid biopsy comes of age /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Biomarkers in cancer therapy/ edited by Hideaki Shimada.
Reminder of title:	liquid biopsy comes of age /
other author:	Shimada, Hideaki.
Published:	Singapore :Springer Singapore : : 2019.,
Description:	viii, 157 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Biochemical markers. -
Online resource:	https://doi.org/10.1007/978-981-13-7295-7
ISBN:	9789811372957

Biomarkers in cancer therapy = liquid biopsy comes of age /
Biomarkers in cancer therapyliquid biopsy comes of age /[electronic resource] :edited by Hideaki Shimada. - Singapore :Springer Singapore :2019. - viii, 157 p. :ill., digital ;24 cm.

I. General Statement -- 1.Exosomes -- 2.Cell Free DNA -- 3.Autoantibody -- 4.Serum Protein -- Part II. Application to Each Cancer -- 5.Head and Neck Cancer / Esophageal Cancer -- 6.Gastric Cancer -- 7.Colorectal Cancer -- 8.Liver Cancer -- 9.Pancreas Cancer -- 10.Lung Cancer -- 11.Breast Cancer -- 12.Prostate Cancer -- 13.Gynecological Cancers -- 14.Malignant Pleural Mesothelioma.

This book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers - all of which serve as the basis for exploring key research questions for future clinical trials in the book's second half. The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy. The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.

ISBN: 9789811372957

Standard No.: 10.1007/978-981-13-7295-7doiSubjects--Topical Terms:

582469
Biochemical markers.

LC Class. No.: QH438.4.B55 / B566 2019

Dewey Class. No.: 572.86

Biomarkers in cancer therapy = liquid biopsy comes of age /
LDR:02726nam a2200325 a 4500 001 940703
003 DE-He213
005 20191106153505.0
006 m d
007 cr nn 008maaau
008 200417s2019 si s 0 eng d
020 $a 9789811372957 $q (electronic bk.)
020 $a 9789811372940 $q (paper)
024 7 $a 10.1007/978-981-13-7295-7 $2 doi
035 $a 978-981-13-7295-7
040 $a GP $c GP
041 0 $a eng
050 4 $a QH438.4.B55 $b B566 2019
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 572.86 $2 23
090 $a QH438.4.B55 $b B615 2019
245 0 0 $a Biomarkers in cancer therapy $h [electronic resource] : $b liquid biopsy comes of age / $c edited by Hideaki Shimada.
260 $a Singapore : $c 2019. $b Springer Singapore : $b Imprint: Springer,
300 $a viii, 157 p. : $b ill., digital ; $c 24 cm.
505 0 $a I. General Statement -- 1.Exosomes -- 2.Cell Free DNA -- 3.Autoantibody -- 4.Serum Protein -- Part II. Application to Each Cancer -- 5.Head and Neck Cancer / Esophageal Cancer -- 6.Gastric Cancer -- 7.Colorectal Cancer -- 8.Liver Cancer -- 9.Pancreas Cancer -- 10.Lung Cancer -- 11.Breast Cancer -- 12.Prostate Cancer -- 13.Gynecological Cancers -- 14.Malignant Pleural Mesothelioma.
520 $a This book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers - all of which serve as the basis for exploring key research questions for future clinical trials in the book's second half. The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy. The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.
650 0 $a Biochemical markers. $3 582469
650 0 $a Cancer $x Treatment. $3 661325
650 1 4 $a Oncology. $3 593951
650 2 4 $a Cancer Research. $3 668358
700 1 $a Shimada, Hideaki. $3 1227508
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-981-13-7295-7
950 $a Medicine (Springer-11650)